Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is ...

Studies have shown that lectin pathway activation contributes to multiple human diseases such as immunoglobulin A nephropathy (IgAN), hematopoietic stem-cell transplantation–associated ...

OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.

Complement Targeted Medicine, IgA Nephropathy, And Why You Should Pay Attention To Omeros Mar. 15, 2018 9:03 AM ET Omeros Corporation (OMER) Stock OMER 53 Comments 12 Likes George Crist 1.48K ...

“Glomerular complement deposition is common in IgA nephropathy, and there is mounting evidence that the lectin pathway is a key complement player in the disease,” said committee member Dr ...

Breakthrough therapy designation for OMS721 for the IgA nephropathy indication was based on data from Omeros’ Phase II study in patients with kidney diseases including IgA nephropahy, which ...

Omeros Corporation today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy. Treatment with ...

TST004 is a humanized mAb targeting mannose-binding protein-associated serine protease 2 (MASP2) and designed to prevent the lectin pathway complement-mediated inflammation. Transcenta discovered ...

DelveInsight’s IgA nephropathy pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for IgA nephropathy treatment.New York, USA, Dec. 14, 2022 ...

Specifically, TST004 inhibits mannose-binding protein-associated serine protease 2 (MASP2), which plays an important role in the lectin pathway activation that leads to diseases like IgA nephropathy.

New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy ...